![UNODC World Drug Report 2024](/files/styles/card/public/2024-07/1a.png?h=8606d1af&itok=MnRRWnjp)
![UNODC World Drug Report 2024](/files/styles/card/public/2024-07/1a.png?h=8606d1af&itok=MnRRWnjp)
Despite extensive evidence regarding the negative effects of stigma experienced by people living with HIV (PLHIV) and people who inject drugs within health care settings, comparatively little evidence exists regarding the effectiveness of...
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
Substance use disorders (SUDs) are highly prevalent and impact individuals' health, well-being, and social functioning. Long-lasting changes in brain networks involved in reward, executive function, stress reactivity, mood, and...
Presented by Richard Rawson, PhD, Emeritus Professor in the Department of Psychiatry and Biobehavioral Science, UCLA School of Medicine and a Research Professor at the University of Vermont, this presentation provided an overview of the...
In the magazine CIJ Informa, the participation of CIJ, host chapter institution of ISSUP Mexico, in the 71st Regular Session of CICAD is reviewed.
The Anti-Stigma Network has been launched!
The Anti-Stigma Network has been created by a group of organisations coming together with a shared mission.
Collectively they aim to improve understanding of the stigma and...
Background
Opioid dependence is associated with substantial health and social burdens, and opioid agonist treatment (OAT) is highly effective in improving multiple outcomes for people who receive this treatment. Methadone and...
The crisis of opioid use puts a strain on resources in the United States and worldwide. There are 3 US Food and Drug Administration–approved medications for treatment of opioid use disorder: methadone, buprenorphine...
Question What treatments for cocaine use disorder are associated with objective reductions in cocaine use among adults?
Findings In this meta-analysis of 157 clinical trials comprising 402 treatment groups and 15 842...
Гексахидроканнабинол (HHC) және онымен байланысты жартылай синтетикалық каннабиноидтар (ССК) рыноктары қазiргi уақытта ақпараты салыстырмалы түрде шектеулi тез дамып келе жатқан аудандар болып табылады.
1-бөлімде ұсынылған...
Objective: To better understand current developments in the treatment of stimulant use.
Background: Stimulant drugs are second only to cannabis as the most widely used class of illicit drug globally, accounting for 68 million past...
Substance misuse among young people is one of the most public concerns in global health. This study set out to explore treatment barriers among young people in Zimbabwe.
Data was collected through interviews with 30 participants
The...
It has been widely reported that youth alcohol consumption has decreased over recent years. What is the evidence to support this view? What are the implications for alcohol related health harm, promotion of safe drinking and health policy?
...Бұл есепте 2002-2021 жылдар кезеңiн қамтитын Австралияда артық дозаланған және есiрткiден қайтыс болғандар туралы ең соңғы және терең деректер ұсынылған. Бұл 20 жылдан астам уақыт бойы Есірткі трендтері шығарған есірткіні шамадан тыс...
Алкогольді пайдалану және психикалық денсаулық жобасы ECHO - алкогольді пайдаланатын адамдармен жұмыс істеу туралы өзекті және зерттеуге негізделген ақпаратты іздеп жүрген денсаулық сақтау саласының мамандары үшін шығынсыз виртуалды...
Share the Knowledge: ISSUP members can post in the Knowledge Share – Sign in or become a member